Stephen O'Hara is not only the chief executive of OptiBiotix Health (LON:OPTI), but he's the biggest shareholder and is particularly pleased with the dividends that the life sciences business provides.

The business develops compounds to tackle obesity, high cholesterol, diabetes and skin care just and its full year results says O'Hara "we're growing our revenues, we're growing our gross profit and we have money in the bank which we increased 122%."

O'Hara says recent personnel appointments will add real commercial impetus in the pre and probiotic business and allow him to investigate further growth opportunities for the company.